Meenakshi Singh, MD

Meenakshi Singh, MD
Professor and Vice-Chair, Anatomic Pathology
UH L2, Room 766
Stony Brook University Medical Center
State University of New York at Stony Brook
Stony Brook, NY 11794-7025

Ph: 631-444-2221
Fax:  (631) 444-3419
email: Meenakshi.Singh@stonybrook.edu

Education:

Postdoctoral Education:

Academic & Professional Honors:

Clinical Practice:

Dr. Singh is board certified in anatomic and clinical pathology (1997) and holds a post graduation degree in Pathology (1984 India). She is a general surgical pathologist and cytopathologist with subspecialty expertise in breast and gynecologic pathology and is a member of the multidisciplinary teams for breast and gynecologic cancers. She has a special interest in early neoplastic/ premalignant lesions. She has an active leadership role in Quality Management in Anatomic Pathology. 

Research Summary:

Dr. Singh’s research focus is the application of novel and established biomarkers for breast and gynecologic cancers and preneoplastic lesions. She has developed rat models for prevention of mammary cancers and early neoplastic mammary lesions. She uses her skills in biomarker research to help elucidate unanswered clinical questions in breast and gynecologic cancers and is a member of the Gynecologic Oncology Group.

Teaching:

Dr. Singh is active in medical student, resident and fellow education. She has developed courses for gross, breast and gynecologic pathology.  Her online atlases are offered as educational tools and have been accessed both by students and teachers across the globe. She has established and conducted CME conferences for peer education.

Publications:

A.  THESIS for Post Graduation in Pathology

A Histopathologic Study of Malignant Tumors in Children at Christian Medical College & Hospital (1975 to 1982), Ludhiana, India. 
Advisor: (The late) S. D. Khanna, MD. Ph.D. Professor, Pathology, CMCH, India.
Punjab University, India, 1984.

B.  Recent Publications in Peer Reviewed Journals (out of a total of 63)

1. Carneiro C, Hurtubis CA, Singh M and Robinson WA. Desmoid tumors of the right rectus abdominus muscle in postpartum women. Arch Gynecol Obstet. 2008 Nov 20. [Epub ahead of print].
   
2. Brooks G, Borges V, Singh M, Rabinovitch R, Finlayson C and Elias A. A perimenopausal woman with a small ER+/HER2+, node negative breast cancer. Oncology (Williston Park) Oncology (Williston Park) 2008 Oct;22(11):1270-6.
   
3. Singh M, Speolstra NS, Jean A, Howe EN, Shroyer KS, Torkko KC, Clark HR, Darling D, Horwitz KB, Broaddus RR and Richer JK. ZEB 1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.  Modern Pathology 2008 21(7):912-23, Epub May 16, 2008.
   
4. Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Singh M, Bissonnette RP and Haugen BR. In Vivo and Microarray Analysis of the Treatment Effects of a Rexinoid on the Anaplastic Thyroid Carcinoma Cell Line DRO-90. Clinical Cancer Research 2008;14(2), 589-96.
   
5. Raina K, Rajamanickam S, Deep G, Singh M, Agarwal R and Agarwal C. Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. Mol Cancer Therapeutics 2008;7(5):1258-67. Epub Apr 29, 2008.
   
6. Harvell DM, Spoelstra NS, Singh M, Finlayson C, Phang T, Trapp S, Hunter L,  Borges VB, Elias A , KB Horwitz and JK Richer. Molecular Signatures of Response to Neoadjuvant Endocrine Therapy for Breast Cancer. Breast Cancer Res Treat. Epub 9 Mar, 2008.
   
7. Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VB, Elias A , and KB Horwitz. Estrogen regulated gene expression in response to neoadjuvant hormone therapy of breast cancers: Tamoxifen agonist effects dominate in the presence of aromatase inhibitor. Breast Cancer Res Treat. Epub Mar 13, 2008).
   
8. Leslie KK, Walter SA, Stephens JK, Thompson C, Singh, M. Effect of Tamoxifen on endometrial histology, hormone receptors and cervical cytology: a prospective study with follow up. Appl Immunohistochem Mol Morph 2007 Sept; 15(3):284-293.
   
9. Zhang Z, Singh M, Davidson S, Rosen DG, Yang G, Liu J. Activation of BTAK expression in primary ovarian surface epithelial cells carrying heterozygous BRCA mutation. Modern Pathology 2007;20:1078-84. Aug 3, Epub ahead of print.
   
10. Mugler KC, Singh M, Tringler B, Torkko KC, Liu W, Papkoff J, Shroyer KR. B7-H4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl Immunohistochem Mol Morph Dec 2007;15:363-370.
    
11. Bowles DW, Borges V, Urquhart A, Rabinovitch R, Singh M, Finlayson C and Elias A. A woman with estrogen receptor positive breast cancer, micrometastasis in an axillary node and an intermediate Oncotype DX recurrence score. Oncology (Williston Park). 2007 Sept; 21(10):1212-7.
    
12. Mugler K, Marshall C, Hardesty L, Finlayson C, Singh, M. Papillary lesions of the breast. Oncology (Williston Park) June2007, 21(7):871-76.
    
13. Smith HO, Leslie K, Singh M, Qualls CR, Revankar CM, Joste N, Prossnitz. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Ob and Gyn 2007 196(4); pages 386e1-386e11.
    
14. Singh, M., Zaino, R., Brunetto, V., and Leslie, K.K. Relationship of Estrogen Receptor-a and Progesterone Receptors A and B to clinical outcome: A Gynecologic Oncology Group study. Gynecologic Oncology 2007, May 24; [Epub ahead of print]. 106(2):325-33.
    
15. Balmer N, Richer J, Spoelstra N, Lyle PL, Torkko K, Singh M. Steroid receptor coactivator AIB 1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinico-pathologic parameters and biomarkers. Modern Pathology Sep 15’ 2006 [Epub ahead of print]; Modern Pathology 2006:19;1593-1605.

Web Based Scholarly Projects:

• Digital Atlas of Breast Pathology by Meenakshi Singh, MD©
• Digital Atlas of Gynecologic Pathology by Meenakshi Singh, MD ©